By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Stellar Pharmaceuticals Inc. 

201- 82 Wellington Street South

London  Ontario  N6B 2K3  Canada
Phone: 519-434-1540 Fax: 519-434-4382


SEARCH JOBS


Industry
Pharmaceutical






Company News
Stellar Pharmaceuticals Inc. (SLX.V) Enters Into a Partnership With Pfizer Canada Inc. to Promote Gelfoam(R) in Canada 8/23/2012 8:00:35 AM
Health Canada Approves Stellar Pharmaceuticals Inc. (SLX.V)'s CAMBIA(R) for the Treatment of Acute Migraine 3/16/2012 8:35:20 AM
Apricus Biosciences (APRI), Stellar Pharmaceuticals Inc. (SLX.V) Sign MycoVa License Agreement in Canada 1/3/2012 7:48:00 AM
Stellar Pharmaceuticals Inc. (SLX.V) Receives European Approval for NeoVisc(R) Single Dose 9/13/2011 7:12:44 AM
Stellar Pharmaceuticals Inc. (SLX.V) and Watson Pharmaceuticals, Inc. (WPI) Terminate Uracyst(R) Supply and Licensing Agreements 4/13/2011 6:58:09 AM
Stellar Pharmaceuticals Inc. (SLX.V) Announces Retirement of Peter Riehl as CEO, President and Director 1/18/2011 6:45:23 AM
Stellar Pharmaceuticals Inc. (SLX.V) Annouces the Approval of Uracyst(R) by the KFDA in South Korea 1/6/2011 9:32:00 AM
Stellar Pharmaceuticals Inc. (SLX.V) Provides Further Update on the Watson Pharmaceuticals, Inc. (WPI)'s Ur008 Pilot Study of Uracyst(R) 11/16/2010 9:30:39 AM
Watson Pharmaceuticals, Inc. (WPI) Backs off from U.S. Plan for Stellar Pharmaceuticals Inc. (SLX.V)'s Uracyst Bladder Treatment After Study Does Not Meet Primary Endpoints 11/11/2010 6:58:02 AM
Stellar Pharmaceuticals Inc. (SLX.V) Reports Third Quarter 2010 Financial Results 11/9/2010 9:17:50 AM
12345678910...
//-->